Loading
A phase 2 trial of Cisplatin, Gemcitabine and Bevacizumab in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] is a phase 2 interventional study registered as NCT07111546 by Nanjing Leads Biolabs Co.,Ltd, with 140 participants planned, started 2025-10-20 and due to reach its primary completion in 2027-12-26. Interventions recorded: LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection and Bevacizumab Injection.
Shares Nanjing Leads Biolabs, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BTC, Gemcitabine and the tag pipeline.
Shares Gemcitabine, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Gemcitabine, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.